Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ITGAV_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ITGAV_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ITGAV_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ITGAV_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ITGAV_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ITGAV_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ITGAV_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ITGAV_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003158913 | Lung | AIS | cell-substrate adhesion | 80/1849 | 363/18723 | 3.80e-12 | 3.16e-09 | 80 |
GO:001603213 | Lung | AIS | viral process | 85/1849 | 415/18723 | 4.74e-11 | 1.95e-08 | 85 |
GO:005105611 | Lung | AIS | regulation of small GTPase mediated signal transduction | 66/1849 | 302/18723 | 4.26e-10 | 9.53e-08 | 66 |
GO:001905813 | Lung | AIS | viral life cycle | 68/1849 | 317/18723 | 5.39e-10 | 1.16e-07 | 68 |
GO:200123313 | Lung | AIS | regulation of apoptotic signaling pathway | 71/1849 | 356/18723 | 6.10e-09 | 9.87e-07 | 71 |
GO:004671813 | Lung | AIS | viral entry into host cell | 38/1849 | 144/18723 | 1.13e-08 | 1.68e-06 | 38 |
GO:005212613 | Lung | AIS | movement in host environment | 43/1849 | 175/18723 | 1.29e-08 | 1.88e-06 | 43 |
GO:005170113 | Lung | AIS | biological process involved in interaction with host | 47/1849 | 203/18723 | 2.09e-08 | 2.90e-06 | 47 |
GO:004440913 | Lung | AIS | entry into host | 38/1849 | 151/18723 | 4.50e-08 | 5.24e-06 | 38 |
GO:004440313 | Lung | AIS | biological process involved in symbiotic interaction | 58/1849 | 290/18723 | 1.33e-07 | 1.44e-05 | 58 |
GO:004578513 | Lung | AIS | positive regulation of cell adhesion | 77/1849 | 437/18723 | 3.40e-07 | 2.83e-05 | 77 |
GO:000689812 | Lung | AIS | receptor-mediated endocytosis | 50/1849 | 244/18723 | 4.47e-07 | 3.52e-05 | 50 |
GO:000722912 | Lung | AIS | integrin-mediated signaling pathway | 28/1849 | 107/18723 | 1.11e-06 | 7.51e-05 | 28 |
GO:200123413 | Lung | AIS | negative regulation of apoptotic signaling pathway | 46/1849 | 224/18723 | 1.19e-06 | 8.00e-05 | 46 |
GO:003010012 | Lung | AIS | regulation of endocytosis | 40/1849 | 211/18723 | 4.10e-05 | 1.23e-03 | 40 |
GO:009719113 | Lung | AIS | extrinsic apoptotic signaling pathway | 41/1849 | 219/18723 | 4.46e-05 | 1.33e-03 | 41 |
GO:005123512 | Lung | AIS | maintenance of location | 55/1849 | 327/18723 | 5.93e-05 | 1.65e-03 | 55 |
GO:200123613 | Lung | AIS | regulation of extrinsic apoptotic signaling pathway | 31/1849 | 151/18723 | 6.27e-05 | 1.70e-03 | 31 |
GO:004825912 | Lung | AIS | regulation of receptor-mediated endocytosis | 24/1849 | 110/18723 | 1.54e-04 | 3.26e-03 | 24 |
GO:200123713 | Lung | AIS | negative regulation of extrinsic apoptotic signaling pathway | 22/1849 | 97/18723 | 1.58e-04 | 3.34e-03 | 22 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0414520 | Cervix | CC | Phagosome | 47/1267 | 152/8465 | 3.95e-07 | 4.26e-06 | 2.52e-06 | 47 |
hsa052226 | Cervix | CC | Small cell lung cancer | 29/1267 | 92/8465 | 4.38e-05 | 3.09e-04 | 1.83e-04 | 29 |
hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa0491918 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa045147 | Cervix | CC | Cell adhesion molecules | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
hsa05418110 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0516319 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0451014 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481017 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa04145110 | Cervix | CC | Phagosome | 47/1267 | 152/8465 | 3.95e-07 | 4.26e-06 | 2.52e-06 | 47 |
hsa0522213 | Cervix | CC | Small cell lung cancer | 29/1267 | 92/8465 | 4.38e-05 | 3.09e-04 | 1.83e-04 | 29 |
hsa0516512 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa0491919 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa0451412 | Cervix | CC | Cell adhesion molecules | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ITGAV | SNV | Missense_Mutation | | c.1264G>A | p.Glu422Lys | p.E422K | P06756 | protein_coding | tolerated(0.45) | benign(0.003) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ITGAV | SNV | Missense_Mutation | | c.2729N>G | p.Leu910Trp | p.L910W | P06756 | protein_coding | tolerated(0.3) | probably_damaging(0.997) | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ITGAV | SNV | Missense_Mutation | | c.147N>G | p.Phe49Leu | p.F49L | P06756 | protein_coding | deleterious(0.02) | probably_damaging(0.97) | TCGA-A8-A0AD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
ITGAV | SNV | Missense_Mutation | | c.323G>C | p.Arg108Thr | p.R108T | P06756 | protein_coding | deleterious(0.02) | benign(0.179) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
ITGAV | SNV | Missense_Mutation | | c.2281T>C | p.Ser761Pro | p.S761P | P06756 | protein_coding | tolerated(0.12) | probably_damaging(0.915) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ITGAV | SNV | Missense_Mutation | rs200733186 | c.2834N>G | p.Asn945Ser | p.N945S | P06756 | protein_coding | deleterious(0.04) | probably_damaging(0.991) | TCGA-OL-A97C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ITGAV | deletion | Frame_Shift_Del | | c.1682delG | p.Gly561AspfsTer2 | p.G561Dfs*2 | P06756 | protein_coding | | | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ITGAV | SNV | Missense_Mutation | | c.1990N>G | p.Gln664Glu | p.Q664E | P06756 | protein_coding | tolerated(1) | benign(0.224) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
ITGAV | SNV | Missense_Mutation | rs201231113 | c.298A>G | p.Ile100Val | p.I100V | P06756 | protein_coding | tolerated(0.12) | benign(0) | TCGA-ZJ-AAXT-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
ITGAV | SNV | Missense_Mutation | rs554897868 | c.2120N>A | p.Arg707His | p.R707H | P06756 | protein_coding | deleterious(0.01) | benign(0.028) | TCGA-4T-AA8H-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL2109621 | ABITUZUMAB | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | antagonist | 348353648 | | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | antagonist | CHEMBL429876 | CILENGITIDE | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | VOLOCIXIMAB | VOLOCIXIMAB | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | CYPATE | CYPATE | 22871580 |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | GLPG0187 | GLPG-0187 | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | CNTO-95 | INTETUMUMAB | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL2109623 | STX-100 | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | Abituzumab | ABITUZUMAB | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | CILENGITIDE | CILENGITIDE | 24095096 |